Insights
Insights From Our Experts
Articles
Webinar: Discover Patient Support Program Needs for Patients with Rare Diseases
In a world where patients face more medication barriers than ever, patient support programs for rare disease patients are critical in providing value-based care that yields a palpable and lasting impact. Manufacturers are acutely aware that…
Bridging the Patient Support Gap With Integrated Technology Solutions and Strategies
Each year, medication non-adherence causes 125,000 preventable deaths and $300 billion in avoidable healthcare costs. In a world where patients face more medication barriers than ever, patient support programs are critical in providing value-based care that…
Getting Treatments to Patients When They Need Them Most: Next Gen Commercialization in Oncology
Commercializing oncology products is extremely complex, but successfully launching new therapies to market is essential for patients and providers in the fight against cancer. In 2020, about 10 million people died from cancer, proving even in…
Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers
Posted by
Franjo Hanzl on September 14, 20219/14/21
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma…
BLOG: Targeting the ‘Right’ Patient — How Pharmaceutical Companies Can Help Physicians Connect Patients to the Right Treatments
Posted by
Dr. Richard Stefanacci on September 10, 20219/10/21
Not every drug is right for every patient, but for some — or the “right” patient — treatment can provide significant clinical and financial benefits. For new therapies, identification of the right patient can be a…
How Manufacturers Can Optimize and Organize Support Services for Specialty Drugs Through a Patient Touchpoint Analysis
Currently representing almost half of the overall pharmacy benefit spend, specialty drugs are classified as being high-complexity, high-touch and high-cost medications. As healthcare providers (HCPs) and patients turn to these more expensive products to treat rare,…
Adapting Patient Access Programs to Asia
In Western markets, pharmaceutical companies have developed many approaches to patient access programs (PAPs), normally emphasizing initiatives that, while helping patients, also support pricing and reimbursement initiatives, such as: Early access programs before market authorization. Financial…
The Patient Access Paradox: How the New CMS Rule Could Prioritize Drug Pricing Before Clinical Decision-Making
In January 2023, co-pay programs will be put to the test, consequently examining how well your brand can adapt to the Final Rule changes to meet patient and provider needs. Our recommendation: Don’t wait – start…
Next Gen Commercialization: Accelerating Patient Access to Life-Changing Therapies
Posted by
Glenn Ravelo on June 29, 20216/29/21
Fifty years ago, only half of the patients diagnosed with cancer in the United States would have been alive five years later. By 2009, patient survival climbed to 70%. The problem is, in all our years working…
Engaging Oncology Patients and Providers in The Age of COVID And Beyond
The engagement model for oncology patients and providers is failing, and challenges brought on by the COVID-19 pandemic have only accelerated the trend. Not only are pharmaceutical reps restricted in the types of information they are…